Research
Hormonal
GLP-1 receptor agonists have shown promising results in reducing liver enzymes and improving MASLD.
Practitioners may consider GLP-1 RAs as a therapeutic option for MASLD.
StrongSupportsmedium confidence
Recently, incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have shown promising results in reducing liver enzymes and improving MASLD.
Why this rating
The claim is supported by a comprehensive literature search.
Source
The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions
Maria Zasadzińska et al. · Journal of Diabetology · 2025
DOI 10.4103/jod.jod_18_25
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →